Skip to content

Kenvue breaks ground on new global headquarters in Summit, New Jersey

Maker of iconic brands such as Neutrogena®, Listerine®, Aveeno® and Tylenol® to establish 290,000 sq. ft global headquarters, including newly constructed, state-of-the-art Science and Innovation Lab

Kenvue Groundbreaking in Summit, NJ

Breaking ground on Kenvue global headquarters in Summit, N.J. on April 24, 2024, from left: Chief People Officer for Kenvue, Luani Alvarado; CEO of NJEDA, Tim Sullivan; Chief Scientific Officer for Kenvue, Caroline Tillett; Governor of New Jersey, Phil Murphy; CEO of Kenvue, Thibaut Mongon; Mayor of Summit, Elizabeth Fagan; Deputy Chief of Staff, Gov. Murphy Eric Brophy; and Chief Operations Officer for Kenvue, Meri Stevens. (Photo by Dave Kotinsky/Getty Images)

Dave Kotinsky/Getty Images

Today, Kenvue, the world’s largest pure-play consumer health company by revenue, hosted a groundbreaking ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey, recognizing the start of construction of its 100,000 sq. ft. state-of-the-art Science and Innovation Lab. Kenvue expects to open its new global headquarters in 2025.

Joined by New Jersey Governor Phil Murphy, Summit Mayor Elizabeth Fagan, MD, and other state and local officials, Kenvue Chief Executive Officer Thibaut Mongon provided insight into the Company’s future global headquarters, which will serve as a collaborative innovation hub and sustainable, digital-first workplace inspired by the Company’s commitment to everyday care.

“With our world-class brands and scientists under one roof, we are poised to unleash the full potential of Kenvue and lead the way in shaping a new era of consumer health through consumer-led and science-driven innovation,” said Thibaut Mongon, Chief Executive Officer, Kenvue. “New Jersey has played an integral role in the success of our iconic brands for more than 135 years, and we are thrilled to strengthen our connection with the state through our new, cutting-edge, world headquarters in Summit.”

“Ensuring that New Jersey is a place where the world’s leading companies want to lay a foundation, expand operations and succeed has been a priority of my administration since I took office,” said New Jersey Governor Phil Murphy. “Given our robust health sector ecosystem, unparalleled scientific workforce, and long history of life-changing innovation, we are thrilled that Kenvue and its iconic brands are calling New Jersey home.”

“We are delighted to welcome Kenvue, a global leader in consumer health, to our vibrant Summit community,” stated Summit Mayor Elizabeth Fagan, MD. “Summit’s reputation as a hub for innovation and business excellence, combined with our access to top-tier talent, makes it the perfect location for Kenvue to call home. We are excited to collaborate closely with Kenvue and support the development of their state-of-the-art facilities.”

Kenvue has a more than 135-year history in New Jersey. By combining the power of science with meaningful human insights and a digital-first approach, Kenvue will be at the forefront of shaping a new era for consumer health with science-driven innovations for iconic brands such as Neutrogena®, Listerine®, Tylenol® and Aveeno®.

# # #

Cautions Concerning Forward-Looking Statements

This media alert contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the Company’s global headquarters in Summit, NJ. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. (“Kenvue”) and its affiliates.

A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and other filings, available at or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.